ArticlePloS one2026
Physician management of immunoglobulin in Canada: A qualitative study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe uses of plasma-derived medical products like Immunoglobulin (Ig) have expanded in recent years. This increasing demand has prompted countries globally to undertake efforts to both increase plasma sufficiency, and develop mitigation measures for shortages in supply, including engaging in demand management.
methodsWe conducted among the first qualitative studies of physician management of Ig in Canada. We used semi-structured interviews and analyzed data with interpretive thematic analysis.
resultsOur findings reflect perspectives from 12 clinicians who prescribe Ig in Canada in the context of rising use of and demand for this treatment. Across the sample, we identified three general orientations toward Ig prescribing: 1, concern and uncertainty about prescribing Ig; 2, good stewardship of a scarce resource; 3, advocacy for access to treatment.
conclusionThis study examined how physicians who prescribe Ig understand their practice in relation to the rising international demand for, and cost of this treatment. To date, policy efforts focusing on physician prescribing have encouraged a rational and evidence-based approach to prescribing. Our study complicates that approach. We identified three general orientations toward Ig prescribing. These should not replace rational prescribing but suggest that a mechanistic approach solely focused on the rational application of the best evidence could be inadequate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.